Kilitch Drugs Reports Mixed Q2 Results, Completes Rights Issue for Greenfield Project

Kilitch Drugs (India) Limited , a prominent pharmaceutical company, has reported mixed financial results for the quarter ended September 30, 2025, while successfully completing a significant rights issue to fund its expansion plans.

Quarterly Performance

The company reported a consolidated net profit of Rs. 4.97 per share for the quarter ended September 30, 2025. However, on a standalone basis, Kilitch Drugs faced challenges, reporting a net loss of Rs. 5.27 per share for the same period.

Financial Highlights

Particulars (Consolidated)	Q2 FY2026 (Rs. in Lakhs)	Q2 FY2025 (Rs. in Lakhs)
Net Sales	4,892.45	4,747.49
Total Income	5,558.49	5,263.91
Total Expenses	4,618.58	4,229.27
Profit Before Tax	939.91	1,034.64
Net Profit	804.00	861.18

Despite the challenges, Kilitch Drugs saw a year-on-year increase in net sales from Rs. 4,747.49 lakhs in Q2 FY2025 to Rs. 4,892.45 lakhs in Q2 FY2026. However, the company experienced a slight decline in net profit, from Rs. 861.18 lakhs to Rs. 804.00 lakhs during the same period.

Successful Rights Issue

A key highlight of the quarter was the completion of a rights issue, which raised Rs. 4,992.51 lakhs. The company issued 13,98,463 fully paid-up Equity Shares at a price of Rs. 357 per share, including a premium of Rs. 347 per share. The proceeds are primarily earmarked for funding capital expenditure at their Greenfield Project in Pen.

Balance Sheet Strengthening

The rights issue has significantly bolstered Kilitch Drugs' financial position. As of September 30, 2025, the company's consolidated balance sheet shows:

Total Assets: Rs. 39,865.53 lakhs (up from Rs. 31,278.38 lakhs as of March 31, 2025)
Equity Share Capital: Rs. 1,748.08 lakhs (increased from Rs. 1,608.23 lakhs)
Other Equity: Rs. 24,817.79 lakhs (up from Rs. 18,624.68 lakhs)

Future Outlook

The successful completion of the rights issue provides Kilitch Drugs with the necessary capital to pursue its expansion plans, particularly the Greenfield Project. This strategic move may potentially strengthen the company's market position and production capabilities in the coming quarters.

While the standalone results show some challenges, the consolidated performance and the influx of capital from the rights issue indicate that Kilitch Drugs is positioning itself for future growth. Investors and stakeholders will likely be watching closely to see how the company utilizes these funds and navigates the evolving pharmaceutical landscape.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.26%	-2.49%	+2.85%	-12.43%	+14.18%	+286.26%

Kilitch Drugs (India) Limited has announced changes to the timeline of its rights issue, affecting the credit and listing dates for the newly issued equity shares. The pharmaceutical company has rescheduled these key dates, pushing them back by one to two days.

Rights Issue Details

Kilitch Drugs is offering a rights issue of 13,98,463 equity shares with a face value of Rs. 10 each. The issue price is set at Rs. 357 per share, which includes a premium of Rs. 347. The total value of the rights issue amounts to Rs. 4,992.51 lakhs. Eligible shareholders can subscribe to the rights issue in the ratio of 2 rights equity shares for every 23 fully paid-up equity shares held as of the record date, which was July 15, 2025.

Revised Timeline

The company has made the following adjustments to the rights issue schedule:

Credit of Rights Equity Shares: Rescheduled from August 25, 2025, to August 26, 2025
Listing of Rights Equity Shares: Moved from August 26, 2025, to August 28, 2025

Allotment Process

According to the LODR (Listing Obligations and Disclosure Requirements) filing, the Board of Directors of Kilitch Drugs met on August 25, 2025, to finalize the basis of allotment and complete the allotment process. The allotment was made in accordance with the terms outlined in the Letter of Offer dated July 12, 2025, and in consultation with MUFG Intime India Private Limited, the Registrar to the Issue.

Impact on Share Capital

Following the rights issue allotment, Kilitch Drugs' paid-up equity share capital has been modified as follows:

Paid-up Share Capital	Number of Shares	Face Value (Rs.)
Pre-Rights Issue	1,60,82,319	10
Post-Rights Issue	1,74,80,782	10

The successful completion of this rights issue represents a significant step for Kilitch Drugs, potentially strengthening its financial position and providing capital for future growth initiatives. Investors and market participants will be closely watching the stock's performance when the newly issued shares are listed on August 28, 2025.

Shareholders and interested parties can find more information about the rights issue on the company's website at https://kilitch.com/investor-relations/ .